| Default purge heparin concentrations (n=63) |
|
| 0 units/mL |
3 (4.8%) |
| 12.5 units/mL |
8 (12.7%) |
| 25 units/mL |
18 (28.6%) |
| 50 units/mL |
33 (52.4%) |
| Other |
1 (1.6%) |
|
| Alternative purge in patients with a contraindication to heparin (n=60) |
|
| Remove anticoagulant from purge |
15 (25.0%) |
| Argatroban |
22 (36.7%) |
| Bivalirudin |
6 (10.0%) |
| Either argatroban or bivalirudin |
7 (11.7%) |
| No strategy developed for this scenario |
10 (16.7%) |
|
| Timing of intravenous heparin initiation (n=61) |
|
| At device insertion, prior to assessing anticoagulation status |
23 (37.7%) |
| Only after the patient is subtherapeutic on the purge solution alone |
30 (49.2%) |
| Other |
8 (13.1%) |
|
| Bolus of heparin administered during intravenous administration (n=61) |
11 (18.0%) |
|
| Intravenous heparin adjusted for initial purge flow (n=61) |
36 (59.0%) |
|
| Default heparin monitoring (n=60) |
|
| Activated partial thromboplastin time |
34 (56.7%) |
| Anti-Xa concentration |
8 (13.3%) |
| Activated clotting time |
13 (21.7%) |
| Other |
5 (8.3%) |
|
| Monitoring for hemolysis is performed routinely (n=60) |
26 (43.3%) |
|
| Hemolysis laboratories monitored (n=26) |
|
| Lactate dehydrogenase |
26 (100.0%) |
| Indirect bilirubin |
13 (50.0%) |
| Serum haptoglobin |
10 (38.5%) |
| Plasma free hemoglobin |
2 (7.7%) |
